Articles related to BIOLOGIC TREATMENTS

A pediatric gastroenterology expert outlines when extrapolation of adult IBD therapies to children is reasonable, where it falls short, and how shared decision-making should be structured.

A 9-member Delphi panel just issued 65 implementation recommendations for anti-amyloid mAbs in private practice. Here’s what counts as practice-shaping and what’s still consensus opinion.

To limit or even avoid the negative impact of ERA and JPsA on patient development, QoL or disease-associated joint damage, rapid and sustained control of disease signs and symptoms is recommended.

“Hidradenitis suppurativa (HS) affects far more than skin; it impacts confidence, emotional well-being and relationships during a formative period for many pediatric patients.” – Brindley Brooks, Founder & CEO, HS Connect.

CMR-guided therapeutic approach decreased rates of recurrence, exposure to glucocorticoids, and pericardiocentesis, demonstrating measurable practice improvements.

Two biologic-naive skin of color patients achieved IGA reduction from 3 to 1 with significant BSA improvement and sustained 6-month follow-up results.